Issues in Oncology

Interventions to Address Sexual Problems in People With Cancer: ASCO Clinical Practice Guideline Adaptation of CCO Guideline

As reported in the Journal of Clinical Oncology by Jeanne Carter, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a clinical practice guideline adaptation of the Cancer Care Ontario...

Issues in Oncology

Legal Duties of Clinicians When Terminally Ill Patients With Cancer or Their Surrogates Insist on ‘Futile’ Treatment

For years, ASCO and other medical societies have lamented the persistent overuse of aggressive end-of-life treatment for patients with incurable cancers. Far too many terminally ill patients receive...

Hematologic Malignancies

The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues

The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment...


More Top Stories

Issues in Oncology

Mary L. Disis, MD, on Basics of Immunology: An Overview

Breast Cancer

No Evidence of Celecoxib Benefit Reported in Patients With Early Breast Cancer

TWO YEARS of treatment with celecoxib had no observed effect on 5-year outcomes of patients with early breast cancer in the large REACT trial presented at the 2017 San Antonio Breast Cancer Symposium.1 “There was no overall benefit observed in disease-free survival or overall survival for...


Fruquintinib in Pretreated Advanced NSCLC

In a Chinese phase II trial reported in the Journal of Clinical Oncology, Lu et al found that the VEGFR-1,-2, and-3 kinase inhibitor fruquintinib was active in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) who progressed after two prior chemotherapy regimens. Study Details ...

Gastroesophageal Cancer

Basem Azab, MD, on Esophageal Cancer: Study Survival Results

Solid Tumors
Breast Cancer

Conqueror in Action: Katherine Reeder-Hayes, MD, Takes on Breast Cancer

When a cutting-edge cancer tool becomes available, marginalized populations such as African Americans and older patients often have less access to it than other populations. This is problematic, especially when those with limited access are those who could benefit the most. As a result, public...

Issues in Oncology
Health-Care Policy

Advancing Cancer Research in Challenging Times

ON OCTOBER 17, 2017, Norman E. Sharpless, MD, became the 15th Director of the National Cancer Institute (NCI), succeeding Harold E. Varmus, MD, who stepped down as Director of the agency in March 2015, and replacing Douglas R. Lowy, MD, who had served as Acting Director for 2 years. The...

Postoperative Chemoradiotherapy vs Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

In an Australia-New Zealand phase III trial (Trans Tasman Radiation Oncology Group 05.01) reported in the Journal of Clinical Oncology, Porceddu et al found no benefit of adding carboplatin to postoperative radiation therapy in patients with high-risk cutaneous squamous cell carcinoma of the head...

Prostate Cancer

James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options

Colorectal Cancer

Small Study Evaluates Treatment Sequencing in Patients With Metastatic Colorectal Cancer

THE OPTIMAL treatment sequence for two approved agents in metastatic colorectal cancer may be regorafenib (Stivarga) before cetuximab (Erbitux), according to results from the small randomized Japanese REVERCE trial presented at the 2018 Gastrointestinal Cancers Symposium.1 Giving regorafenib...


Effect of Single PSA-Based Screening on Prostate Cancer Mortality

In the UK-based CAP trial reported in JAMA, Martin et al found that a single prostate-specific antigen (PSA) screening was not associated with better 10-year prostate cancer-specific survival vs the standard practice of no screening. Screening was associated with greater detection of prostate...